Alterity Therapeutics (NASDAQ:ATHE) Cut to “Hold” at Benchmark

Benchmark lowered shares of Alterity Therapeutics (NASDAQ:ATHE) from a speculative buy rating to a hold rating in a report issued on Monday morning, MarketBeat Ratings reports.

Separately, Maxim Group upped their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th.

Alterity Therapeutics Stock Down 5.8 %

NASDAQ:ATHE opened at $4.25 on Monday. Alterity Therapeutics has a 52-week low of $1.00 and a 52-week high of $5.87. The stock’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $1.89.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its holdings in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.